#1 out of 1,1144.76%
business16h ago
Intellia Therapeutics, Inc. Q1 2026: Revenue $15M, EPS $(0.81) — 10-Q Summary
Tradingview.com and 3 more
- The 2025 divestitures and subsequent segment realignment are intended to streamline the business toward its core rental, infrastructure, and services offerings.
- Capital expenditures in Q1 2026 were $11.7M, largely for expanding the aviation fleet and fiber-optic equipment to support growth.
- Significant channel shift to aviation rentals contributed about $10M of incremental aviation revenue.
Vote 50







